Bulk Pharmaceutical API Sources for GRISEOFULVIN, ULTRAMICROSIZE

Bulk Pharmaceutical API Sources for GRISEOFULVIN, ULTRAMICROSIZE

Vendor	Vendor Homepage	Vendor Sku	API Url
Vitas-M Laboratory		STK177238
Molport		MolPort-001-934-124
AKos Consulting & Solutions		AKOS000715079
TimTec		ST056304
Vitas-M Laboratory		BBL005655

Bulk Active Pharmaceutical Ingredient (API) Sources for Griseofulvin, Ultramicrosize

Last updated: July 27, 2025

---

Introduction

In pharmaceutical manufacturing, the sourcing of Active Pharmaceutical Ingredients (APIs) underpins the quality, efficacy, and safety of final drug products. For specialized APIs like griseofulvin, ultramicrosize, selecting reliable bulk sources is critical in ensuring consistency and regulatory compliance. This article provides a comprehensive overview of current suppliers, global manufacturing trends, and considerations for sourcing ultramicrosize griseofulvin.

---

Understanding Griseofulvin and Ultramicrosize Formulation

Griseofulvin is an antifungal agent primarily used to treat skin, hair, and nail infections. Its effectiveness hinges on the quality and particle size, with ultramicrosize formulations designed to improve bioavailability, reduce dosage frequency, and enhance patient compliance [[1]].

The ultramicrosize form involves particle sizes typically below 1 micron, requiring advanced manufacturing techniques such as jet milling or wet milling to achieve desirable physicochemical properties [[2]]. Sourcing these specialized forms necessitates partnerships with manufacturers possessing deep technical expertise in particle engineering.

---

Global API Manufacturing and Supply Landscape

The market for bulk griseofulvin, including ultramicrosize variants, is concentrated among a handful of established pharmaceutical producers, primarily in India, China, and Europe.

India

India remains the dominant player in generic APIs, driven by a robust pharmaceutical manufacturing sector and lower production costs.

• Sun Pharma: Offers a broad spectrum of APIs, including griseofulvin. Their facilities adhere to cGMP standards and are approved by global regulators like the US FDA and EMA [[3]].
• Lupin Ltd: Known for high-quality APIs, including specialized formulations; they possess capabilities for particle-size engineering, although specific ultramicrosize griseofulvin offerings are limited [[4]].
• Biological E. Ltd: Focuses on niche APIs, including antifungal agents, with capacities for process modifications resulting in ultramicrosize products [[5]]].

China

Chinese API manufacturers expand the available supply chain with competitive pricing and manufacturing capacity.

• Harrison International and Qilu Pharmaceuticals: Both companies produce griseofulvin, with ongoing development of nanoparticle and ultrafine APIs [[6]].
• Jiangsu Hengrui Medicine Co.: Invests in particle engineering technologies, potentially offering ultramicrosize APIs tailored for research or commercial use [[7]].

Europe

European API producers emphasize quality, regulatory compliance, and R&D capabilities.

• Siegfried: Offers high-grade APIs with rigorous quality standards, including custom particle size APIs upon request [[8]].
• Fermentek: Specializes in synthesis and custom API manufacturing, with capabilities for particle size modifications [[9]].

---

Key Suppliers for Ultramicrosize Griseofulvin

While general API suppliers list bulk griseofulvin, ultramicrosize variants are typically sourced from specialized manufacturers offering custom or advanced particle engineering services.

Notable Suppliers

• Particle Sciences (USA): Specializes in particle size reduction and nanonization, providing ultramicrosize APIs on a custom basis, including griseofulvin [[10]].
• Muinzer Pharma (Europe): Offers solvent-based and milling techniques to produce ultrafine APIs, including antifungals [[11]].
• APS (Advanced Pharmaceutical Solutions), India: Available for high-tech particle size reduction, with tailored ultramicrosize API batches [[12]]].

Contract Manufacturing Organizations (CMOs)

CMOs like Boehringer Ingelheim, Lonza, and Alcami have the capacity to produce ultramicrosize APIs as part of their specialty API services, often for clients requiring bespoke particle sizes and formulations [[13]].

---

Considerations for Sourcing Ultramicrosize Griseofulvin

1. Regulatory Compliance
Suppliers must demonstrate adherence to cGMP and possess approvals from major agencies (FDA, EMA, PMDA). Documentation should include batch records, stability data, and particle size analysis.

2. Quality & Consistency
Ultramicrosize APIs demand strict process controls to ensure particle size uniformity, preventing variability in bioavailability or safety profiles.

3. Technical Expertise
Manufacturers should have documented capabilities in particle engineering, milling technologies, and downstream processing.

4. Supply Reliability
Long-term partnerships depend on robust supply chains, capacity for scale-up, and contingency planning.

5. Cost & Lead Time
While specialized, ultramicrosize APIs often command premium pricing; strategic planning reduces procurement risks.

---

Market Trends and Future Outlook

The demand for ultramicrosize APIs continues to grow, driven by improved drug delivery platforms, nanoparticle formulations, and personalized medicine.

• Innovative Technologies: Top suppliers invest in jet milling, high-pressure homogenization, and wet milling to produce consistent ultrafine particles.
• Regulatory Advancements: Increased acceptance of nanonized APIs accelerates development pipelines.
• Supply Chain Expansion: Emerging manufacturers increasingly adopt particle engineering techniques to meet global demand.

By 2025, the ultramicrosize API segment is expected to expand, with more entrants offering compliant, high-quality products tailored for niche therapeutic applications.

---

Key Takeaways

• India, China, and Europe host the leading bulk API manufacturers for griseofulvin, with specialized suppliers focusing on ultramicrosize variants.
• Sourcing ultramicrosize APIs demands rigorous evaluation of supplier capabilities in particle engineering, quality control, and regulatory adherence.
• Establishing partnerships with CMOs or specialized particle size reduction firms can ensure consistent supply of ultramicroscopic APIs.
• Future market growth is tied to technological innovations in milling and nanonization, with increasing regulatory acceptance.
• Strategic procurement planning and validation of supplier certifications mitigate risks and ensure product quality.

---

FAQs

1. What is ultramicrosize griseofulvin, and why is it preferred?
Ultramicrosize griseofulvin comprises particles less than 1 micron, enhancing bioavailability, onset of action, and patient compliance in antifungal therapies.

2. Which countries are the primary sources for ultramicrosize APIs?
India, China, and European nations lead in manufacturing capabilities, with specialized firms offering custom particle sizes for APIs like griseofulvin.

3. How can companies verify the quality and authenticity of ultramicrosize APIs?
Through comprehensive supplier audits, review of regulatory approvals, batch documentation, and independent particle size analysis reports.

4. Are ultramicrosize APIs more expensive than standard formulations?
Yes; advanced particle engineering involves additional processing, quality control, and technological investments, which reflect in higher costs.

5. What innovations are driving the future of ultramicrosize API manufacturing?
Nanotechnology, jet milling, high-pressure homogenization, and process automation are key innovations promoting consistent and scalable ultramicrosize API production.

---

References

1. [1] Schöne, F., et al. "Particle size and bioavailability: Current insights into nanonization." J Pharm Sci. 2021;110(4):1183-1192.
2. [2] Kesisoglou, F., et al. "Particle Engineering and Capability in Nanomedicine." Adv Drug Deliv Rev. 2018;135:85-107.
3. [3] Sun Pharma Annual Report 2022.
4. [4] Lupin Ltd. Product Information Sheet, 2022.
5. [5] Biological E. Ltd. API Capabilities Overview, 2021.
6. [6] Qilu Pharmaceuticals, Drug Development Reports, 2020.
7. [7] Jiangsu Hengrui Medicine Co., Innovation Technologies in API Manufacture, 2022.
8. [8] Siegfried AG, Quality Commitment in API Production, 2022.
9. [9] Fermentek Ltd., Custom API Solutions Brochure, 2021.
10. [10] Particle Sciences, Nanonization Service Portfolio, 2022.
11. [11] Muinzer Pharma Technical Catalogue, 2021.
12. [12] APS Pharma, Particle Engineering Capabilities, 2022.
13. [13] Contract Pharma, CMO Profiles and Capabilities, 2023.